Balyasny Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.7M Buy
812,718
+325,882
+67% +$3.61M 0.01% 1214
2026
Q2
$11.7M Buy
486,836
+189,713
+64% +$5.75M 0.01% 985
2026
Q1
$9.03M Sell
297,123
-55,875
-16% -$1.49M 0.01% 1078
2025
Q4
$10.2M Buy
+352,998
New +$4.61M 0.01% 1020
2024
Q4
– Sell
-14,999
Closed -$228K – 2782
2024
Q3
$228K Buy
+14,999
New +$74.2K ﹤0.01% 2526
2024
Q2
– Sell
-12,994
Closed -$88.2K – 2613
2024
Q1
$88.2K Buy
+12,994
New +$62.8K ﹤0.01% 2502

Other funds holding CAPR

Balyasny Asset Management's CAPR Position: Q3 2026 in Review

Balyasny Asset Management increased its Capricor Therapeutics (CAPR) stake by 67% in Q3 2026, buying an estimated $3.61M and bringing the position to 812,718 shares worth $7.7M. The position accounts for 0.01% of the portfolio, ranked #1214.

Balyasny Asset Management first reported a position in CAPR in Q1 2024 and has held it in 6 quarters since. The position peaked at $11.7M in Q2 2026. 158 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Balyasny Asset Management held 812,718 shares of Capricor Therapeutics worth $7.7M as of Q3 2026.
  • Balyasny Asset Management bought 325,882 Capricor Therapeutics shares in Q3 2026, an estimated $3.61M.
  • Capricor Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q3 2026, its #1214 holding.
  • Balyasny Asset Management first reported a position in Capricor Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Balyasny Asset Management's Capricor Therapeutics position peaked at $11.7M in Q2 2026.
  • 158 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.